Pancreatic Cancer Research

ResearcherNanjing University of Chinese MedicineActive in the last 2 years

Changchang Lu

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5108514142. Sources: OpenAlex.

Their work

Papers
10 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
24
Papers, trials and grants by year

2021: 1 paper · 2022: 6 papers · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper

Papers 10

  1. Tumor-penetrating peptide boosts bispecific T-cell engager antitumor efficacy for the pancreatic cancer. Co-author DOI 10.3389/fimmu.2025.1693755↗
  2. Efficacy and safety of second-line therapy by S-1 combined with sintilimab and anlotinib in pancreatic cancer patients with liver metastasis: a single-arm, pha… First author DOI 10.3389/fimmu.2024.1210859↗
  3. Biomarkers for predicting tumor response to PD-1 inhibitors in patients with advanced pancreatic cancer. Co-author DOI 10.1080/21645515.2023.2178791↗
  4. Efficacy and safety of immune checkpoint inhibitors in advanced pancreatic cancer: A real world study in Chinese cohort. Co-author DOI 10.1080/21645515.2022.2143154↗
  5. Advanced Pancreatic Cancer Patient Benefit From Personalized Neoantigen Nanovaccine Based Immunotherapy: A Case Report. Co-author DOI 10.3389/fimmu.2022.799026↗
  6. Use of Nab-Paclitaxel Plus Gemcitabine Followed by Hypofractionated Tomotherapy With Simultaneous Integrated Boost in Patients With Locally Advanced Pancreatic… Co-author DOI 10.3389/fonc.2022.782730↗
  7. Molecular Landscape and Prognostic Biomarker Analysis of Advanced Pancreatic Cancer and Predictors of Treatment Efficacy of AG Chemotherapy. Co-author DOI 10.3389/fonc.2022.844527↗
  8. Study protocol for a prospective, open-label, single-arm, phase II study on the combination of tislelizumab, nab-paclitaxel, gemcitabine, and concurrent radiot… Co-author DOI 10.3389/fonc.2022.879661↗
  9. Case Report: Pathologic Complete Response to Induction Therapy in a Patient With Potentially Resectable Pancreatic Cancer. Co-author DOI 10.3389/fonc.2022.898119↗
  10. AGIG Chemo-Immunotherapy in Patients With Advanced Pancreatic Cancer: A Single-Arm, Single-Center, Phase 2 Study. Co-author DOI 10.3389/fonc.2021.693386↗

Closest collaborators

The 24 strongest of 24 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xin Qiu · 9 shared papers, 2021–2024 · strength 1.34
  2. Baorui Liu · 9 shared papers, 2021–2024 · strength 1.34
  3. Juan Du · 7 shared papers, 2021–2024 · strength 1.09
  4. Qiao-Li Wang · 3 shared papers, 2022–2024 · strength 0.52
  5. Fan Tong · 3 shared papers, 2022–2024 · strength 0.52
  6. Lei Wang · 3 shared papers, 2022 · strength 0.37
  7. Yudong Qiu · 3 shared papers, 2022 · strength 0.37
  8. Qi Li · 3 shared papers, 2022 · strength 0.37
  9. Huizi Sha · 2 shared papers, 2021–2024 · strength 0.35
  10. Zhan Shi · 2 shared papers, 2022–2023 · strength 0.34
  11. Linxi Zhu · 2 shared papers, 2022 · strength 0.25
  12. Juan Du · 2 shared papers, 2022 · strength 0.25
  13. Jun Chen · 2 shared papers, 2022 · strength 0.25
  14. Juan Du · 1 shared paper, 2025 · strength 0.24
  15. Lu Zou · 1 shared paper, 2025 · strength 0.24
  16. Juan Liu · 1 shared paper, 2022 · strength 0.16
  17. Jie Shao · 1 shared paper, 2022 · strength 0.14
  18. Xiaoling Gong · 1 shared paper, 2022 · strength 0.14
  19. Yujie Zhou · 1 shared paper, 2022 · strength 0.14
  20. Wangshu Dai · 1 shared paper, 2021 · strength 0.14
  21. Jian He · 1 shared paper, 2022 · strength 0.13
  22. Xin Zhang · 1 shared paper, 2022 · strength 0.13
  23. Ju Dong Yang · 1 shared paper, 2022 · strength 0.12
  24. Hao Cheng · 1 shared paper, 2022 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.